Wassberg E, Påhlman S, Westlin J E, Christofferson R
Department of Human Anatomy, University of Uppsala, Sweden.
Pediatr Res. 1997 Mar;41(3):327-33. doi: 10.1203/00006450-199703000-00004.
A new animal experimental model of human neuroblastoma is described. The model involves xenotransplantation of a poorly differentiated human neuroblastoma cell line (SH-SY5Y) to the subcutaneous tissue in the hind leg of nude rats (WAG mu/rnu). Injection of 20 million cells suspended in 0.2 mL of medium in each hind leg yielded an 89% tumor take (41/46) in 23 nude rats. Tumor take was evident after 2 wk. The tumors grew exponentially and reached a volume of 5.2 +/- 1.6 mL 4 wk after transplantation. The tumor cells retained their morphologic phenotype at the ultrastructural level after transplantation and were immunohistochemically positive for neuron-specific enolase and for chromogranins A and B. Subcutaneous injections of the angiogenesis inhibitor TNP-470 (10 mg/kg of body weight) every other day gave a treated/control quotient for mean tumor volume of 0.34 after 12 d of treatment. This implies that angiogenesis inhibition may be of value as a complement to chemotherapy in the treatment of human neuroblastoma. The presented animal experimental model is designed for investigations of the effects of chemotherapy, angiogenesis inhibitors, radiotherapy, and/or surgery on the growth rate of human neuroblastoma.
本文描述了一种新的人类神经母细胞瘤动物实验模型。该模型涉及将一种低分化人类神经母细胞瘤细胞系（SH-SY5Y）异种移植到裸鼠（WAG mu/rnu）后腿的皮下组织。在每只后腿注射悬浮于0.2 mL培养基中的2000万个细胞，在23只裸鼠中产生了89%的肿瘤形成率（41/46）。2周后肿瘤形成明显。肿瘤呈指数生长，移植后4周体积达到5.2±1.6 mL。移植后肿瘤细胞在超微结构水平保留其形态学表型，并且神经元特异性烯醇化酶以及嗜铬粒蛋白A和B免疫组化呈阳性。每隔一天皮下注射血管生成抑制剂TNP-470（10 mg/kg体重），治疗12天后治疗组/对照组平均肿瘤体积的比值为0.34。这意味着血管生成抑制作为人类神经母细胞瘤化疗的补充可能具有价值。所呈现的动物实验模型旨在研究化疗、血管生成抑制剂、放疗和/或手术对人类神经母细胞瘤生长速率的影响。
